drugset / Trial / NCT00509249
Aflibercept in Treating Patients With Myelodysplastic Syndromes
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying how well aflibercept works in treating patients with myelodysplastic syndromes. Aflibercept may be able to carry cancer-killing substances directly to myelodysplastic syndrome cells. It may also stop the growth of cancer cells by blocking blood flow to the cancer
Timeline
- Start
- 2007-09
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped: “Early termination for discouraging results”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 4 mg/kg | Intravenous |